Details
Stereochemistry | ACHIRAL |
Molecular Formula | C5F12 |
Molecular Weight | 288.0343 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F
InChI
InChIKey=NJCBUSHGCBERSK-UHFFFAOYSA-N
InChI=1S/C5F12/c6-1(7,2(8,9)4(12,13)14)3(10,11)5(15,16)17
DescriptionSources: http://ec.europa.eu/health/documents/community-register/1998/199807173235/anx_3235_en.pdfCurator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/9383597 and http://www.thepharmaletter.com/article/first-approval-for-sonus-echogen
Sources: http://ec.europa.eu/health/documents/community-register/1998/199807173235/anx_3235_en.pdf
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/9383597 and http://www.thepharmaletter.com/article/first-approval-for-sonus-echogen
Perflenapent (EchoGen, Sonus Pharmaceuticals, Bothel, WA, USA) is a transpulmonary echocardiographic contrast agent for use in patients with suspected or established cardiovascular disease to provide opacification of cardiac chambers, enhance left ventricular border delineation with resulting improvement in wall motion visualisation. EchoGen comprises liquid droplets of dodecafluoropentane stabilised by polyfluoroalkyl(polyoxyethylene)
ethanol and dispersed in an aqueous formulation containing sucrose. Dodecafluoropentane is the chemical name used to reflect the perflenapent/perflisopent mixture. Following activation and administration of
EchoGen, dodecafluoropentane microbubbles are formed. EchoGen should only be used in patients where the study without contrast enhancement is inconclusive. The European Commission has approved SONUS Pharmaceuticals' EchoGen (perflenapent emulsion) in all 15 countries of the European Union. EchoGen is a fluorocarbon-based ultrasound contrast agent which has been approved as a transpulmonary echocardiographic contrast agent for use in patients with suspected or established cardiovascular disease who have had previous inconclusive non-contrast studies. Additional approved labeling in the EU states that the use of EchoGen in spectral and color Doppler studies was shown to enhance the visualization of blood flow across mitral, aortic and tricuspid valves in a subset of patients. In 2000 SONUS Pharmaceuticals withdrew the NDA for EchoGen in the USA.
Originator
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | EchoGen Approved UseEchoGen is a transpulmonary echocardiographic contrast agent for use in patients with suspected or
established cardiovascular disease to provide opacification of cardiac chambers, enhance left ventricular
border delineation with resulting improvement in wall motion visualisation.
EchoGen should only be used in patients where the study without contrast enhancement is inconclusive. Launch Date1994 |
PubMed
Title | Date | PubMed |
---|---|---|
Radiosensitization of hypoxic tumor cells by dodecafluoropentane: a gas-phase perfluorochemical emulsion. | 2002 Jul 1 |
|
In vivo droplet vaporization for occlusion therapy and phase aberration correction. | 2002 Jun |
|
On the acoustic vaporization of micrometer-sized droplets. | 2004 Jul |
|
A respiration-metabolism chamber system and a GC-MS method developed for studying exhalation of perfluorobutane in rats after intravenous injection of the ultrasound contrast agent Sonazoid. | 2005 Sep 15 |
|
Intravascular fluorocarbon-stabilized microbubbles protect against fatal anemia in rats. | 2006 |
|
Value of adenosine infusion for infarct size determination using real-time myocardial contrast echocardiography. | 2006 Feb 8 |
|
Determination of reference ultrasound parameters for model and hydrofluoroalkane propellants using high-resolution ultrasonic spectroscopy. | 2008 |
|
Towards aberration correction of transcranial ultrasound using acoustic droplet vaporization. | 2008 Mar |
|
Elaborating the phase behaviour of ethylene oxide oligomers and analogues in 2H, 3H-perfluoropentane. | 2008 Oct 1 |
|
Environmental hazards and health risk of common liquid perfluoro-n-alkanes, potent greenhouse gases. | 2009 Feb |
|
Comparison of surfactants used to prepare aqueous perfluoropentane emulsions for pharmaceutical applications. | 2010 Apr 6 |
|
Fluid adsorption in ordered mesoporous solids determined by in situ small-angle X-ray scattering. | 2010 Jul 14 |
|
Partitioning and phase equilibria of PEGylated excipients in fluorinated liquids. | 2010 Mar 15 |
Patents
Sample Use Guides
Adults and the Elderly
Administer perflenapent (EchoGen) as an intravenous bolus at a dose of 0.05 ml/kg and at a rate of 1 ml/sec.
Route of Administration:
Intravenous
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
507515
Created by
admin on Fri Dec 15 15:34:47 GMT 2023 , Edited by admin on Fri Dec 15 15:34:47 GMT 2023
|
||
|
NCI_THESAURUS |
C390
Created by
admin on Fri Dec 15 15:34:47 GMT 2023 , Edited by admin on Fri Dec 15 15:34:47 GMT 2023
|
||
|
NCI_THESAURUS |
C798
Created by
admin on Fri Dec 15 15:34:47 GMT 2023 , Edited by admin on Fri Dec 15 15:34:47 GMT 2023
|
||
|
WHO-ATC |
V08DA03
Created by
admin on Fri Dec 15 15:34:47 GMT 2023 , Edited by admin on Fri Dec 15 15:34:47 GMT 2023
|
||
|
FDA ORPHAN DRUG |
497715
Created by
admin on Fri Dec 15 15:34:47 GMT 2023 , Edited by admin on Fri Dec 15 15:34:47 GMT 2023
|
||
|
WHO-VATC |
QV08DA03
Created by
admin on Fri Dec 15 15:34:47 GMT 2023 , Edited by admin on Fri Dec 15 15:34:47 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
ECHOGEN (WITHDRAWN: ECHOCARDIOGRAPHY)
Created by
admin on Fri Dec 15 15:34:47 GMT 2023 , Edited by admin on Fri Dec 15 15:34:47 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
211-647-5
Created by
admin on Fri Dec 15 15:34:47 GMT 2023 , Edited by admin on Fri Dec 15 15:34:47 GMT 2023
|
PRIMARY | |||
|
483AU1Y5CZ
Created by
admin on Fri Dec 15 15:34:47 GMT 2023 , Edited by admin on Fri Dec 15 15:34:47 GMT 2023
|
PRIMARY | |||
|
483AU1Y5CZ
Created by
admin on Fri Dec 15 15:34:47 GMT 2023 , Edited by admin on Fri Dec 15 15:34:47 GMT 2023
|
PRIMARY | |||
|
4685
Created by
admin on Fri Dec 15 15:34:47 GMT 2023 , Edited by admin on Fri Dec 15 15:34:47 GMT 2023
|
PRIMARY | |||
|
12675
Created by
admin on Fri Dec 15 15:34:47 GMT 2023 , Edited by admin on Fri Dec 15 15:34:47 GMT 2023
|
PRIMARY | |||
|
DB11625
Created by
admin on Fri Dec 15 15:34:47 GMT 2023 , Edited by admin on Fri Dec 15 15:34:47 GMT 2023
|
PRIMARY | |||
|
DTXSID3046613
Created by
admin on Fri Dec 15 15:34:47 GMT 2023 , Edited by admin on Fri Dec 15 15:34:47 GMT 2023
|
PRIMARY | |||
|
2474632
Created by
admin on Fri Dec 15 15:34:47 GMT 2023 , Edited by admin on Fri Dec 15 15:34:47 GMT 2023
|
PRIMARY | |||
|
SUB12493MIG
Created by
admin on Fri Dec 15 15:34:47 GMT 2023 , Edited by admin on Fri Dec 15 15:34:47 GMT 2023
|
PRIMARY | |||
|
100000089107
Created by
admin on Fri Dec 15 15:34:47 GMT 2023 , Edited by admin on Fri Dec 15 15:34:47 GMT 2023
|
PRIMARY | |||
|
PERFLENAPENT
Created by
admin on Fri Dec 15 15:34:47 GMT 2023 , Edited by admin on Fri Dec 15 15:34:47 GMT 2023
|
PRIMARY | |||
|
7528
Created by
admin on Fri Dec 15 15:34:47 GMT 2023 , Edited by admin on Fri Dec 15 15:34:47 GMT 2023
|
PRIMARY | |||
|
678-26-2
Created by
admin on Fri Dec 15 15:34:47 GMT 2023 , Edited by admin on Fri Dec 15 15:34:47 GMT 2023
|
PRIMARY | |||
|
39428
Created by
admin on Fri Dec 15 15:34:47 GMT 2023 , Edited by admin on Fri Dec 15 15:34:47 GMT 2023
|
PRIMARY | |||
|
GG-108A
Created by
admin on Fri Dec 15 15:34:47 GMT 2023 , Edited by admin on Fri Dec 15 15:34:47 GMT 2023
|
PRIMARY | |||
|
CHEMBL1899801
Created by
admin on Fri Dec 15 15:34:47 GMT 2023 , Edited by admin on Fri Dec 15 15:34:47 GMT 2023
|
PRIMARY | |||
|
C87703
Created by
admin on Fri Dec 15 15:34:47 GMT 2023 , Edited by admin on Fri Dec 15 15:34:47 GMT 2023
|
PRIMARY |
ACTIVE MOIETY